A randomized, open-label study of the effect of PEGASYS [peginterferon alfa-2a] plus either amantadine or ribavirin on serum HCV-RNA [hepatitis C virus-RNA] and ALT [alanine aminotransferase] levels/correction in previously untreated patients with chronic hepatitis C viral infection.

Trial Profile

A randomized, open-label study of the effect of PEGASYS [peginterferon alfa-2a] plus either amantadine or ribavirin on serum HCV-RNA [hepatitis C virus-RNA] and ALT [alanine aminotransferase] levels/correction in previously untreated patients with chronic hepatitis C viral infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2010

At a glance

  • Drugs Amantadine; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 25 Jun 2007 Status change
    • 08 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top